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Abstract
Angiogenesis or neovascularization, the process of new blood vessel formation from preexisting microvasculature,
involves interactions among several cell types including parenchymal, endothelial cells, and immune cells. The for-
mation of new vessels is tightly regulated by a balance between endogenous proangiogenic and antiangiogenic fac-
tors to maintain homeostasis in tissue; tumor progression and metastasis in breast cancer have been shown to be
angiogenesis-dependent. We previously introduced a systematic methodology to identify putative endogenous anti-
angiogenic peptides and validated these predictions in vitro in human umbilical vein endothelial cell proliferation and
migration assays. These peptides are derived from several protein families including type IV collagen, CXC chemo-
kines, and thrombospondin-1 domain-containing proteins. On the basis of the results from the in vitro screening,
we have evaluated the ability of one peptide selected from each family named pentastatin-1, chemokinostatin-1,
and properdistatin, respectively, to suppress angiogenesis in an MDA-MB-231 human breast cancer orthotopic xeno-
graft model in severe combined immunodeficient mice. Peptides were administered intraperitoneally once per day.
We have demonstrated significant suppression of tumor growth in vivo and subsequent reductions in microvascular
density, indicating the potential of these peptides as therapeutic agents for breast cancer.
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Introduction
The area of tumor angiogenesis gained attention owing to the pioneer-
ing work of Judah Folkman [1], who discovered that neovascular for-
mation was necessary for tumor growth and development. Without
a stable blood supply, the tumor would be dependent on oxygen dif-
fusion and be unable to grow past a critical volume or metastasize. The
process of neovascular formation involves interactions among several
types of cells including endothelial cells, pericytes, vascular smooth
muscle cells, parenchymal cells, as well as cell–extracellular matrix in-
teractions. Many growth factors are involved including vascular endo-
thelial growth factor (VEGF), fibroblast growth factor, platelet-derived
growth factor, and angiopoietins [2,3].
Abbreviations:HUVECs, human umbilical vein endothelial cells; SCID, severe combined
immunodeficient; TSP-1, thrombospondin-1; VEGF, vascular endothelial growth factor
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In normal vascular homeostasis, blood vessels are maintained through
a balance of proangiogenic or antiangiogenic factors, whereas pathologies
dependent on neovascular development can occur through a resulting
imbalance. The progression of solid tumors occurs when a tumor ac-
quires its own blood supply by upregulating proangiogenic factors [4]
and is associated with an increase in vascular density [5].
Breast cancer is the most commonly diagnosed female malignancy
in the United States, proving fatal to nearly 40,000 people in 2007
with 184,000 additional diagnosed cases [6]. Angiogenesis has been
shown to play a key role in breast cancer development, invasion, and
metastasis [7–12]. Clinical evidence of angiogenesis in breast cancer is
abundant. Intratumoral microvascular density is elevated [5,13], and
VEGF expression is increased [13–15] in patients with breast cancer.
These factors correlate with a shorter relapse-free and overall survival
[16]. Anti-VEGF therapies have shown promise in clinical trials [10]
and an anti-VEGF antibody bevacizumab (Roche/Genentech) has been
approved by the Food and Drug Administration for breast cancer in
2008 in combination with chemotherapy. Other agents, for example,
targeting VEGF receptors, are also in clinical trials [17]. Yet, despite the
promise of anti-VEGF therapeutics, it has been suggested that targeting
the principal angiogenic factor VEGF alone may never suffice to erad-
icate malignant tumors, and alternative options should be developed
to complement the current VEGF-based therapies with strategies that
target other angiogenic factors [2]. It has also been proposed that anti-
angiogenic therapies may function to stabilize the structurally and func-
tionally abnormal vasculature of the tumor (vascular normalization),
resulting in the more effective delivery of chemotherapeutic agents [18].
During the last two decades, a number of endogenous angiogenesis
inhibitors have been identified [19–23]. Many of these endogen-
ous inhibitors contain cryptic sites or active sites that are normally hid-
den from the environment within the protein structure. Once released
through proteolytic processing of the proteins, these fragments can act
as modulators of neovascular formation. A collection of proteins that con-
stitutes the angiogenesis-inhibiting endogenous regulatory elements ex-
ists, balancing the angiogenic switch by counteracting the effects of the
various growth factors stimulating angiogenesis [20].
Recently, we have developed a bioinformatics-based approach to
identify more than 100 novel putative endogenous antiangiogenic
peptides [24]. The peptides are derived from several protein families
with localized antiangiogenic properties including type IV collagen,
CXC chemokines, and thrombospondin-1 (TSP-1) domain-containing
proteins [25–27]. The activity of these peptides and validity of the
approach were experimentally verified in several in vitro angiogenesis
assays, including the migration and proliferation of human umbilical
vein endothelial cells (HUVECs). This article describes the application
of three selected peptides – one from each family – to an in vivoMDA-
MB-231 breast cancer orthotopic xenograft model, which resulted in
tumor suppression and decreases in microvascular density.
Materials and Methods
In Vitro Cell Viability Assay Using Human MDA-MB-231
Breast Cancer Cells and Mouse 3T3 Fibroblasts with
Application of Peptides Pentastatin-1, Chemokinostatin-1,
and Properdistatin
Cell culture. In vitro proliferation assays were completed with each
peptide on MDA-MB-231 breast cancer and mouse 3T3 fibroblast
cell lines. The MDA-MB-231 cells were acquired from a single donor
(ATCC, Manassas, VA). The cells were propagated in RPMI-1640 me-
dium (Cambrex, Walkersville, MD) with 10% FBS and antibiotics
(penicillin/streptomycin) under standard conditions of 37°C and 5%
CO2. 3T3 mouse fibroblast cells were acquired from ATCC and grown
under standard conditions in Dulbecco’s modified Eagle medium
(ATCC) with 10% FBS.
Peptide synthesis and handling. The following peptides were
synthesized using a solid-phase synthesis technique by a commercial
provider (Abgent, San Diego, CA): Pentastatin-1 derived from the
α5 fibril of type IV collagen (both human and mouse sequence:
LRRFSTMPFMFCNINNVCNF), chemokinostatin-1 derived from
CXCL1 (human sequence used in vitro on MDA-MB-231 cells,
NGRKACLNPASPIVKKIIEKMLNS; mouse sequence used in vitro
on 3T3 cells and in vivo, NGREACLDPEAPMVQKIVQKMLKG),
and properdistatin derived from protein properdin (human sequence,
GPWEPCSVTCSKGTRTRRR; mouse sequence, GPWGPCSVTC-
SKGTQIRQR). Table 1 summarizes the peptide sequences and their
proteins of origin. The peptides were stored at temperatures of −80°C.
HPLC and mass spectrometry analysis of each peptide were provided
by the manufacturer to demonstrate greater than 95% purity. The
hydrophobic peptide, pentastatin-1, was solubilized using 10% di-
methyl sulfoxide (DMSO) without any demonstrated effect on cell
viability. Chemokinostatin-1 and properdistatin were solubilized in
PBS before use.
In vitro cell viability assay. The antitumor effects of the peptides
on the MDA-MB-231 cell line were measured using the colorimetric
cell proliferation reagent WST-1 (Roche, Indianapolis, IN). Approxi-
mately 2 × 103 cells were seeded per well in a 96-well microplate
and were exposed for 3 days to several different peptide concentra-
tions of 1, 10, 20, 30, 40, 50, 80, and 100 μg/ml. Cells were tested
in quadruplicate for each concentration. As an experimental control,
equivalent to normal cell viability, the cells were cultured without any
agent in complete medium containing growth factors and serum with-
out any exposure to peptide. Effects on the viability of 3T3 fibro-
blasts were conducted in a similar fashion with peptides applied at the
same concentrations.
Table 1. Amino Acid Sequences of the Tested Peptides.
Peptide Name Peptide Origin Accession No. Peptide Sequence (Human/Mouse)
Pentastatin-1 α5 fibril of collagen IV AAF66217 (1516-1535) LRRFSTMPFMFCNINNVCNF
LRRFSTMPFMFCNINNVCNF
Chemokinostatin-1 CXCL1/Gro-α P00341 (80-103) NGRKACLNPASPIVKKIIEKMLNS
NGREACLDPEAPMVQKIVQKMLKG
Properdistatin Properdin AAB63280.1 (143-161) GPWEPCSVTCSKGTRTRRR
GPWGPCSVTCSKGTQIRQR
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Statistical analysis. Statistical significance for in vitro results was
assessed using the Student’s t-test, with P < .01 defined as significant.
In vivo results were tested using both the Student’s t-test at P < .05 and
the nonparametric Wilcoxon rank sum test. Peptides were compared
with the experimental control and scrambled peptide equivalent. Tumor
volumes were measured on days 1, 4, 7, 10, and 13, and the average
tumor size per condition was reported over time. The SEM is reported.
Translation from in vitro to selected in vivo peptides. On the
basis of our previous in vitro results [25–27], we selected one peptide with
both significant antiproliferative and antimigratory activity from three
dominant peptide families: type IV collagen, CXC chemokines, and
TSP-1 domain-containing peptides to test in vivo in breast xenografts.
In vivo tumor xenograft models. Animal protocols were approved
by the Institutional Care andUseCommittee at the JohnsHopkinsMed-
ical Institutions ( JHMI). A population of MDA-MB-231 breast cells
were washed twice in PBS and gently resuspended in RPMI medium
to generate a single cell suspension. Subsequently, the cells were injected
into the mammary fat pad of severe combined immunodeficient (SCID)
mice at a concentration of 2 million cells/100-μl solution. After growth
incubation of 14 to 21 days, tumor volumes were calculated from
measurements of tumor dimensions with calipers. Tumor growth was
monitored to an initial average size of 75 to 100 mm3, which usually
developed within 21 days after inoculation. Peptides were administered
once per day, intraperitoneally, in doses of 10 mg/kg for pentastatin-1,
and 20 mg/kg for chemokinostatin-1 and properdistatin. The more
hydrophobic peptide, pentastatin-1, was dissolved in 10% DMSO and
90% H2O to ensure solubility before administration. Equivalent vol-
umes of PBS solution were injected as an experimental control. Separate
controls of scrambled peptide sequences were also made for each pep-
tide tested to provide proof that the antiangiogenic efficacy of the novel
peptides was sequence-dependent. The injections were continued for
13 days with a total of eight animals per group used for each condition.
Immunohistochemistry. Immediately after the sacrifice of mice, tu-
mors were excised and stored in a zinc-based fixative (BD Biosciences,
San Jose, CA) for 10 to 14 days and processed by the JHMI Immuno-
histochemistry Core Facility. Paraffin sections of 5 μm were obtained
from the central cross-sectional volume of each tumor. After deparaffini-
zation and rehydration, the sections were treated overnight with a mono-
clonal rat antimouse CD31 platelet endothelial cell adhesion molecule
immunoglobulin G antibody (BD PharMingen, San Jose, CA), which
specifically recognizes an epitope on the surface of endothelial cells.
Each tumor section was also subsequently processed and stained using
hematoxylin-eosin (H&E) stain to visualize tissue structure and core ne-
crotic regions in the tumor. Histologic samples were processed using
Aperio Image Scope Software (Aperio Technologies, Inc, Vista, CA),
quantified using FRiDA software ( JohnsHopkins University, Baltimore,
MD), and scaled as a percentage of the experimental control. Each pep-
tide was compared with the experimental control and scrambled peptide
equivalent using the Student’s t-test at P < .05.
Additional staining was made to assess the origin and proliferation
status of single cells within the tumor microenvironment using fluo-
rescence costaining for telomeric DNA to differentiate human from
murine cells and the proliferative marker Ki67 (Figure 5) by the JHMI
Immunohistochemistry Core Facility as previously described [28].
Briefly, deparaffinized slides were processed with citrate buffer (Vector
Laboratories, Burlingame, CA), placed in PBS with Tween (Sigma,
St Louis, MO), followed by ethanol, and then air-dried. Slides were
then treated with 25 μl of a Cy3-labeled telomere-specific peptide nucleic
acid (PNA) at 0.3 μg/ml PNA in 70% formamide, 10 mMTris, pH 7.5,
0.5% B/M blocking reagent (catalog no. 1814-320; Boehringer-
Mannheim, Indianapolis, IN). Slides were then further processed for
indirect immunofluorescence by application of primary antibody (anti-
Ki67, catalog no.NCL-Ki67p, diluted 1:1200; Novocastra Laboratories,
Newcastle uponTyne, UK) followed by application of the goat antirabbit
IgG fraction Alexa Fluor 488 fluorescent secondary antibody (catalog no.
A-11001, diluted 1:100; Molecular Probes, Invitrogen, Carlsbad, CA).
Next, nuclei were counterstained with 4′-6-diamidino-2-phenylindole
(DAPI) at 500 ng/ml in deionized water (catalog no. D-8417; Sigma
Chemical Co). The PNA probe complementary to the mammalian
telomere repeat sequence was obtained from Applied Biosystems
(Framingham, MA) and has the sequence (N-terminus to C-terminus)
CCCTAACCCTAACCCTAA with an N-terminal covalently linked
Cy3 fluorescent dye.
Slides were imaged with a Nikon 50i epifluorescence microscope
equipped with X-cite series 120 illuminator (EXFOPhotonics Solutions,
Inc, Ontario, Canada) and a 100×/1.4 NA oil immersion Neofluar
lens. Fluorescence excitation/emission filters were as follows: Cy3 excita-
tion, 546nm/10nmBP; emission, 578nmLP (Carl Zeiss Inc,Germany);
DAPI excitation, 330 nm; emission, 400 nm through an XF02 fluores-
cence set (Omega Optical, Brattleboro, VT); Alexa Fluor 488 excitation,
475 nm; emission, 535 nm through a combination of 475RDF40 and
535RDF45 filters (Omega Optical). Signal capture ranged from 16 milli-
seconds for the DAPI counterstain, 510 milliseconds for fluorescein
isothiocyanate (centromere), and 200 milliseconds for Cy3 (telomere)
with six images taken per condition. Images were then processed using
Image J software (US National Institutes of Health, Bethesda, MD)
to preserve fluorescence intensity. Images were then overlain and com-
piled using Adobe Photoshop CS3 Software (Adobe Systems, Inc,
San Jose, CA). Pixel intensity and cell counts were also approximated
using Adobe Photoshop.
Results
Endothelial cells, tumor cells, and surrounding fibroblasts can all be
sensitive to peptide inhibitors. In vitro viability experiments were con-
ducted on two different cell lines, MDA-MB-231 breast tumor cells
and mouse 3T3 fibroblasts, after 3 days of incubation with peptide.
Figure 1 shows the dose-response of pentastatin-1 applied to MDA-
MB-231 tumor cells, showing maximal activity at concentrations
greater than 50 μg/ml, and 3T3 fibroblasts, showing maximal activity
at concentrations greater than 40 μg/ml. There were no significant dif-
ferences between peptide-treated wells and the experimental control
shown in both cell lines for chemokinostatin-1 and properdistatin (data
not shown), although they have been previously shown to inhibit the
migration and proliferation of HUVECs [24,26,27].
Once in vitro studies were completed, each peptide was administered
intraperitoneally to MDA-MB-231 xenograft-bearing mice. Mice were
inoculated with 2 × 106 cells/100 μl, and tumors were allowed to grow
for 14 to 21 days until reaching an average volume of 75 to 100 mm3.
Each condition contained n = 8 animals and was compared with an
experimental PBS-treated control, shown in Figure 2. In a separate ex-
periment, 10% DMSO and PBS-treated controls were tested to show
if there was no significant difference due to DMSO (data not shown).
Scrambled peptide controls were also tested and showed no significant
difference from the PBS- or DMSO-treated controls at any day (data
not shown). Pentastatin-1 treatment resulted in a significant tumor
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growth suppression throughout the duration of the experiment as
determined by the Student’s t-test and the Wilcoxon statistical analysis
except for day 7 when only the Student’s t-test showed significance.
Nonetheless, differences in tumor growth were significant for the re-
mainder of the experiment compared with the experimental control.
Chemokinostatin-1 treatment also resulted in a significant suppression
of tumor growth compared with the experimental control, with the
exception of day 13 for which the Wilcoxon statistical analysis and
the Student’s t-test both showed a nonsignificant result. In this case,
tumor volumes at days 10 and 13 were also not significantly differ-
ent compared with the scrambled peptide equivalent. Properdistatin-
treated tumors showed a significant volume change from the PBS
controls and scrambled peptide treated throughout the duration of
the experiment by both the Student’s t-test and the Wilcoxon test.
As shown in Figure 2B, by day 13, tumors in the experimental control
group had grown by an average of 275% from starting values at the
onset of injections, whereas pentastatin-1–treated tumors increased by
150%, chemokinostatin-1–treated tumors increased by 170%, and
properdistatin-treated tumors increased by 153%. Throughout the
duration of the experiment, toxicity was monitored by weight changes
in the mice, and peptide-treated groups were shown to have no statisti-
cally significant change from the control. Additional H&E staining of
vital organ sections including lung, liver, and kidney showed no ab-
normal pathologies in any condition, summarized in Figure W1.
Figure 3 shows H&E staining from the experimental control and
peptide-treated tumors at 1× and 2× magnifications. It can be seen that
the pentastatin-1– and properdistatin-treated tumors have increased
central necrosis in the tumor microenvironment as indicated by arrows
on the photomicrographs. Chemokinostatin-1–treated tumors appeared
to be similar to the control group with less necrotic areas. Immuno-
histochemistry was also performed on tumor xenografts postmortem
after tumors had been fixed in zinc-containing solution and stained
with a CD31 antibody, a common marker for vessels and endothelial
cells. Figure 4A shows decreases in vascularization in pentastatin-1–,
chemokinostatin-1–, and properdistatin-treated tumors at 20× magnifi-
cation as indicated by the lower amount of CD31 staining. Figure 4B
shows microvascular density quantification for each peptide based on
endothelial cell staining by CD31. Results for scrambled peptide equiva-
lents were not significantly different from the respective experimental
controls. Pentastatin-1 had a significant decrease in vessel density in com-
parison to the experimental control, whereas chemokinostatin-1 showed
a decrease in microvascular density in comparison to both the experi-
mental control and its scrambled peptide equivalent. Properdistatin also
showed some reduction in vascular density from its scrambled peptide
equivalent and experimental control, although the results were not sta-
tistically significant.
Figure 5A shows the results of fluorescence costaining for Ki67
proliferating cells (green) and mouse cells (red ). DAPI (blue), which
specifically stains cell nuclei, was used for estimating cell numbers as
shown in the composite images (left panel ). Qualitatively, the peptide-
treated tumors show a reduction in proliferating cells for pentastatin-1,
chemokinostatin-1, and properdistatin at the time of termination and
fixation. Figure 5B shows the quantification of the fluorescence in the
photomicrographs of Figure 5A as an estimate of the number of prolifer-
ating cells and mouse stromal cell composition in the tumors. The con-
trols show on average 38% proliferating cells in the tumor and 21%
mouse stromal cells. Pentastatin-1 and chemokinostatin-1 show 16%
and 26% proliferating cells, respectively, whereas properdistatin shows a
statistically lower percentage at 14%. The percentages of mouse stromal
cells in pentastatin-1 and properdistatin are not statistically different from
Figure 1. In vitro proliferation results for pentastatin-1 on MDA-
MB-231 breast tumor cells and 3T3 fibroblasts. Cell viability was de-
termined using a WST-1 colorimetric assay at the end of a 72-hour
exposure to peptide. Data are scaled so that 100% represents the
signal from the experimental control and thus maximum viability.
Cells were treated at concentrations of 1, 10, 20, 30, 40, 50, 80,
and 100 μg/ml of peptide. Pentastatin-1, at high concentrations, de-
creased viability of 3T3 fibroblasts and MDA-MB-231 breast cancer
cell lines in vitro in this assay. Statistical significance is determined
at P < .01, and the vertical error bars represent the SEM.
Figure 2. (A) MDA-MB-231 breast xenograft growth in SCID mice
with application of threepeptides derived from threeprotein families.
Cells were inoculated orthotopically into the mammary fat pad with
2 × 106 cells/mouse, and tumors were allowed to grow for 14 to
21 days to an average of 75 to 100 mm3 on peptide administration.
The average tumor volume (n = 8) is plotted every fourth day after
treatment. Tumor volumes are statistically different from the control
at P < .05 by Student’s t-test for all days except chemokinostatin-1
on day 13. Scrambled peptide equivalents were also tested in vivo
and were not statistically different from the experimental control.
(B) Tumor percent change is also shown from the starting tumor
values on peptide administration.
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the control, whereas the chemokinostatin-1–treated tumors show a
marked 67% stromal cell fraction in the tumor microenvironment.
Discussion
Endogenous peptides with antiangiogenic activity have emerged as one
of the leading tools to treat cancer in addition to polypeptides, small
molecules, and antibodies [29]. We have previously introduced a sys-
tematic methodology for the identification of antiangiogenic peptide
sequences and demonstrated that a high percentage of the predicted
peptides indeed inhibit the proliferation and migration of HUVECs
in vitro. On the basis of this in vitro screening, we selected one mole-
cule from three protein classes—pentastatin-1, a collagen IV–derived
peptide; chemokinostatin-1, a CXC chemokine–derived peptide; and
properdistatin, a TSP-1 domain-containing peptide—and tested them
in vitro on additional cell lines and in vivo in an orthotopic MDA-MB-
231 breast xenograft model.
We demonstrated in vitro that pentastatin-1 has anticellular effects
on MDA-MB-231 cells and decreases 3T3 fibroblast viability; how-
ever, chemokinostatin-1 and properdistatin do not exhibit these effects.
The latter peptides have been previously shown to exhibit antiprolifera-
tive and antimigratory properties on HUVECs [26,27]. Pentastatin-1
has also been previously shown to inhibit proliferation and migration of
endothelial cells in vitro [25], and we demonstrated inhibition of tumor
growth in vivo. Supplementary flow cytometry data in Figure W2
show receptor identification of β1-integrins for MDA-MB-231 cells.
Pentastatin-1 has been previously shown to bind to β1-integrins [24],
which we show are present in high percentages for both HUVECs at
85% of cells andMDA-MB-231 at 79% of cells, indicating that the pep-
tide is capable of directly inhibiting tumor cell proliferation in addition to
being antiangiogenic. Chemokinostatin-1 was similarly shown to bind
to CXCR3 through antibody neutralization experiments, and proper-
distatin was shown to bind to the CD36 receptor [24]. Both of these
peptides inhibit the proliferation of HUVECs; however, they did not
inhibit tumor cell proliferation or proliferation of 3T3 fibroblasts. Flow
cytometry data indicate a low percentage of these receptors in MDA-
MB-231 cells, suggesting that the activity of these peptides is likelymono-
modal and localized only to proliferating endothelial cells.
The three endogenous peptides show significant tumor suppression
at the concentrations of 10 mg/kg for pentastatin-1 and 20 mg/kg for
both chemokinostatin-1 and properdistatin. The scrambled peptide con-
trols strongly suggest the efficacy of the peptides is sequence-dependent.
Although randomly mutating peptide amino acid sequences does not
guarantee the resulting sequence will not retain some binding inter-
actions among receptor families, in this case the scrambled sequences
only retain nominal activity, which was not statistically significant from
the experimental controls.
Immunohistochemistry was performed using the CD31 anti-
body, which is specific for endothelial cells. In pentastatin-1– and
chemokinostatin-1–treated tumors, there is a statistically significant
inhibition of endothelial cells and a reduction in microvessel volume,
indicating that the peptides are antiangiogenic. Chemokinostatin-1–
treated tumors grew more rapidly toward the end of the experiment,
indicating possible endothelial cell resistance to the peptide. In our
H&E staining of tumor cross sections on day 13, we found that
chemokinostatin-1 is most similar to the experimental control, con-
taining minimal core necrotic regions, suggesting the peptide’s less
deleterious effect on the tumor microenvironment. We also show that
in chemokinostatin-1–treated mice, their tumors have a higher per-
centage of proliferating cells than the pentastatin-1– or properdistatin-
treated tumors. The significant quantity of mouse stromal cells suggests
a high infiltration of these cells into the tumor microenvironment owing
to the presence of the chemokine-derived peptide. Chemokinostatin-1
is notably derived from the proangiogenic ELR-positive CXC chemo-
kines. The cancer biology of CXC chemokines is complex because these
Figure 3. H&E staining of tumor cross sections at 1× and 2× for the experimental control, pentastatin-1, chemokinostatin-1, and proper-
distatin. Pentastatin-1– and properdistatin-treated tumors show increased necrotic regions (arrows), whereas chemokinostatin-1 is most
similar to the control.
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peptides may stimulate the infiltration of various stromal cells into
the tumor microenvironment [30]. Although the SCID mice used in
this experiment lack T and B lymphocytes, there may be an influx of
other mouse stromal cells into the tumor owing to the presence of the
chemokine-derived peptide.
The experiments were terminated after day 13 of treatment because
some peptide-treated tumors had begun to escape and grew as rapidly
as the controls, indicating tumor resistance to the applied peptides. Re-
cently, it has been proposed that there can be at least two underlying
mechanisms for resistance to antiangiogenic therapies: adaptive or
evasive resistance and intrinsic nonresponsiveness [31]. On the basis
of the initial response phase of peptide treatment we observed in the
case of each peptide, we hypothesize a form of adaptive resistance de-
veloped within the tumor microenvironment in response to the peptide
treatment. Recent systematic investigation of resistance to endogenous
antiangiogenic agents (TSP-1, endostatin, and tumstatin) demonstrates
that tumors escape the treatments after several days, and a number of
proangiogenic factors (e.g., VEGF, FGF-2, transforming growth factor-β)
are upregulated [4]. Other general mechanisms of resistance include
the recruitment of bone marrow–derived proangiogenic cells, increased
pericyte coverage in the tumor vasculature, and increased activation
of invasion and metastasis for access to normal tissue vasculature
[31]. Future studies should be performed to determine the modes of
Figure 4. (A) Immunohistochemistry showing CD31 antibody stain-
ing in several conditions as a marker for endothelial cells and vessel
density. Images were taken at 20× magnification for the experimen-
tal control, pentastatin-1–, chemokinostatin-1–, and properdistatin-
treated tumors. (B) Quantification of endothelial cells and vessel
density for resulting cross sections scaled to the experimental con-
trol. Each condition was quantified by pixel intensity representing
the quantity of endothelial cells. The type IV collagen–derived peptide,
pentastatin-1, andCXCchemokine–derivedpeptide, chemokinostatin-1,
werestatisticallydifferent fromthecontrol atP<.05.Chemokinostatin-1
was also statistically significant from its scrambled peptide control,
showing a reduction in endothelial cells and vasculature.
Figure 5. (A) Fluorescence costain for Ki67 proliferating cells (green)
and murine cells by telomeric DNA (red). Composite images are
made with DAPI (blue) as a stain for cell nuclei (left panel). Cell
counts are approximated using pixel intensity with Image J and
Adobe Photoshop CS3 software. Qualitatively, the pentastatin-1–,
chemokinostatin-1–, and properdistatin-treated tumors contain fewer
proliferating cells than the control. (B) Quantification of proliferating
cells and mouse stromal cells. Controls contained an average of
38% proliferating cells and 21% mouse stromal cells. Properdistatin
contained a statistically significant reduction in proliferating cells with
14% proliferating. Chemokinostatin-1 contained a statistically signifi-
cant increase in mouse stromal cells from the controls, with 67% of
the tumor microenvironment of this type, suggesting an infiltration of
murine-derived cells into the tumor microenvironment.
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resistance for each peptide and whether treatment efficacy can be fur-
ther sustained. Despite these initial limitations, the peptides have a po-
tential to regulate and suppress vessel growth in vivo and in translational
studies possibly when combined with cytotoxic agents or in combina-
tions with other antiangiogenic agents.
Breast cancer has been shown to be angiogenesis-dependent; thus,
advances in the development of antiangiogenic agents should con-
tribute to the arsenal of therapeutic tools available for treatment of
the disease. The presented results indicate the selected peptides may
have the potential for translational clinical therapeutics in breast can-
cer. In summary, we have demonstrated that systematically identified
peptides derived from type IV collagen, CXC chemokines, and TSP-1
inhibit neovascularization in MDA-MB-231 breast xenografts and are
candidates for translational therapeutics in breast cancer.
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Supporting Materials and Methods
Fixation of vital organs. Severe combined immunodeficient mice
with MDA-MB-231 breast xenografts were humanely killed after
13 days of treatment with peptides or PBS using CO2. Liver, lungs,
and kidneys were excised and stored in zinc-based fixative (BD Bio-
sciences) for 3 weeks, after which samples were placed in paraffin
blocks. H&E staining was made to visualize tissue structure for pa-
thology and normal tissue structure in comparison to the experimen-
tal control. Histologic samples were processed using Aperio Image
Scope Software (Aperio Technologies) and compiled using Adobe
Photoshop CS3 Software (Adobe Systems).
Flow cytometry analysis for receptor identification. Flow cytome-
try analysis was completed for receptor quantification on primary
HUVECs and MDA-MB-231 breast cancer cells. HUVECs were
acquired from a single donor were purchased from Cambrex. Cells
were propagated in endothelial growth medium-2 (Lonza, Basel, Switzer-
land) using 2% FBS, growth factors (human basic fibroblast growth
factor and VEGF), and antibiotics (gentamicin/amphotericin B). All
cells usedwere from passage 3 to passage 6.MDA-MB-231breast cancer
cells were acquired from a single donor (ATCC) as described previously
and propagated in RPMI-1640 medium (Cambrex) with 10% FBS and
antibiotics (penicillin/streptomycin). Cells were gently dissociated from
their flasks using PBS/EDTA (200 mg/ml), counted, and aliquoted at
5 × 105 cells/ml in medium. Heat-aggregated human IgG at 20 μg/ml
was used to block nonspecific binding. Medium containing different
monoclonal antibody solutions at 20 μl/1 × 106 cells were applied for
β1-integrins (FAB17781; R&D Systems, Minneapolis, MN), CXCR3
(FAB1685; R&D Systems), and CD36 (CB38/NL07; BD PharMingen).
Cells were then incubated for 60 minutes at 4°C to allow binding of re-
ceptors to antibody, pelleted after centrifuging at 1000 RPM for 5 minutes
at 4°C, and washed with a 200-μl medium of 1% FBS three times. Three
hundredmicroliters of buffer (PBS, 1%BSA, 0.1%NaN3; Sigma-Aldrich,
Inc) was applied and transferred to FACS tubes. Flow cytometry analysis
and protocols were followed using the FACSCalibur (BD Biosciences),
and receptors were quantified using FlowJo Flow Cytometry Analysis Soft-
ware (Tree Star, Inc, Ashland, OR).
Figure W1. Peptide-treated tumors and their respective vital organs using H&E staining on day 13. Gross tissue morphology is shown in
(A) for kidney at 1×, and (B) normal lung structure at 1×. (C) Liver sections were taken and magnified at 4× to show consistent mor-
phology in control and peptide-treated tumors. (D) Kidney, (E) lung, and (F) liver were magnified at 20× to show normal cell structure and
the absence of pathologies due to peptide delivery.
Figure W2. Flow cytometry analysis for receptor identification on HUVECs andMDA-MB-231 cells. (A) Phycoerythrin conjugation for CXCR3
identification on HUVECs and MDA-MB-231 cells, showing 5.3% cells contain the receptor in HUVECs and 2.9% in MDA-MB-23s. Similar
analysis shows HUVECs contain the β1-integrin receptor in 84.5% of cells, and 78.8% of MDA-MB-231 cells. Fluorescein isothiocyanate
conjugation for CD36 revealed 4.4% of HUVECs and 2.9% of MDA-MB-231 cells contain the receptor. (B) The corresponding table sum-
marizes the ratios of these receptors in HUVEC/MDA-MB-231 cells as 1.9 for CXCR3, 1.1 for β1-integrins, and 1.5 for CD36.
